The firm has also announced the first patient treatment with a Halcyon system equipped with HyperSight at Penn Medicine on a cancer patient
Varian gets CE Mark and 510(k) clearance for Halcyon and Ethos Radiotherapy Systems featuring HyperSight. (Credit: Varian Medical Systems, Inc.)
Varian, a Siemens Healthineers company, has secured both 510(k) clearance from the US Food and Drug Administration (FDA) and CE mark for its Halcyon and Ethos radiotherapy systems featuring its HyperSight technology.
HyperSight helps clinicians in capturing high-quality images of patients during their daily radiation treatments. The images are utilised for the daily localisation of patient tumours.
According to Varian, the software enables images to be used for replanning and adaptation to patient and tumour changes.
The medical device firm said that HyperSight utilises cone-beam computed tomography (CBCT) technology which produces larger images with better contrast.
Additionally, the technology is claimed to be 10 times faster than traditional linear accelerator-based imaging systems. It also saves patients’ time and has the potential to considerably improve patient experience, said the company.
Varian said that conventional CBCT imaging can take up to 60 seconds and needs patients to hold their breath a number of times in order to obtain a complete, clear image. HyperSight is said to take images in six seconds with the potential to minimise patient anxiety and discomfort while offering clearer images.
Varian radiation oncology solutions president Kevin O’Reilly said: “Varian has long been focused on pioneering innovations that can enhance the radiotherapy experience and outcomes for both patients and cancer care teams.
“Becoming a Siemens Healthineers company has given us an opportunity to sharpen and accelerate these efforts, with a focus on connecting the power of imaging inside and outside the treatment room. HyperSight reflects the power of our expanded view of the patient journey and robust imaging technology.
“We look forward to working with our clinical partners and the broader radiotherapy community to drive adoption and further advancement of this technology, as we continue our work to transform the patient pathway and deliver on our mission to create a world without fear of cancer.”
In addition, the Siemens Healthineers company announced the first patient treatment with a Halcyon system equipped with HyperSight at Penn Medicine on a cancer patient.
As per the firm, HyperSight technology also enables the calculation of radiation dose distributions directly on CBCT images.